Key result
QTc prolongation was significantly more frequent in HAART-naïve HIV patients (32%) compared to HIV patients on HAART (17.3%) and healthy controls (4.7%).
Why the study?
Does first line HAART use increase the risk of QTc prolongation in HIV patients?
Population
300 subjects comprising 150 HIV positive patients and 150 age and sex-matched healthy controls.
Comparison
First line Highly Active Anti-Retroviral Therapy vs HAART-naïve HIV patients and healthy controls
Design
Cross-sectional
Authors
Loading...
May warrant QTc vigilance in untreated HIV; cross-sectional data leaves open causality and clinical impact.
Cross-Sectional (n=300)
No
Does first line HAART use increase the risk of QTc prolongation in HIV patients?
Absolute Event Rate: 17.3% vs 32%
p-value: p=<0.001
First line HAART use in HIV patients is not associated with QTc prolongation; rather, untreated HIV infection and lower CD4 counts are associated with longer QTc intervals.
Ogunmodede et al. (2017) conducted a cross-sectional in HIV/AIDS (n=300). Highly Active Anti-Retroviral Therapy (HAART) vs. HAART-naïve HIV patients was evaluated on Frequency of QTc prolongation (p=<0.001). QTc prolongation was significantly more frequent in HAART-naïve HIV patients (32%) compared to HIV patients on HAART (17.3%) and healthy controls (4.7%).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: